DK0876818T3 - Middel til behnadling af nerodegenerative lidelser - Google Patents

Middel til behnadling af nerodegenerative lidelser

Info

Publication number
DK0876818T3
DK0876818T3 DK96935637T DK96935637T DK0876818T3 DK 0876818 T3 DK0876818 T3 DK 0876818T3 DK 96935637 T DK96935637 T DK 96935637T DK 96935637 T DK96935637 T DK 96935637T DK 0876818 T3 DK0876818 T3 DK 0876818T3
Authority
DK
Denmark
Prior art keywords
neurodegenerative disorders
treating neurodegenerative
remedy
nmda
indoles
Prior art date
Application number
DK96935637T
Other languages
Danish (da)
English (en)
Inventor
Nikolai Serafimovich Zefirov
Andrei Zakharovich Afanasiev
Svetlana Vasilievna Afanasieva
Sergei Evgenievich Tkachenko
Vladimir Viktorovich Grigoriev
Marina Abramovna Jurovskaya
Valery Pavlovich Chetverikov
Elizaveta Evgenievna Bukatina
Irina Vladimirovna Grigorieva
Sergei Olegovich Bachurin
Original Assignee
Selena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selena Pharmaceuticals Inc filed Critical Selena Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0876818T3 publication Critical patent/DK0876818T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DK96935637T 1995-10-23 1996-10-23 Middel til behnadling af nerodegenerative lidelser DK0876818T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU95118252A RU2106864C1 (ru) 1995-10-23 1995-10-23 Средство для лечения болезни альцгеймера
PCT/RU1996/000306 WO1997015225A1 (fr) 1995-10-23 1996-10-23 Agent therapeutique contre les troubles neurodegeneratifs

Publications (1)

Publication Number Publication Date
DK0876818T3 true DK0876818T3 (da) 2003-03-31

Family

ID=20173218

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96935637T DK0876818T3 (da) 1995-10-23 1996-10-23 Middel til behnadling af nerodegenerative lidelser

Country Status (11)

Country Link
US (6) US6187785B1 (de)
EP (1) EP0876818B1 (de)
AT (1) ATE229806T1 (de)
AU (1) AU7347496A (de)
CA (1) CA2269698C (de)
DE (1) DE69625518T2 (de)
DK (1) DK0876818T3 (de)
ES (1) ES2188793T3 (de)
HK (1) HK1016893A1 (de)
RU (1) RU2106864C1 (de)
WO (1) WO1997015225A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
CA2363244C (en) * 2000-11-07 2006-06-13 Research In Motion Limited Multifunctional keyboard for a mobile communication device and method of operating the same
WO2004035580A1 (en) * 2002-10-21 2004-04-29 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
RU2283108C2 (ru) * 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20070179174A1 (en) * 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
FR2885905A1 (fr) * 2005-05-23 2006-11-24 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament
WO2007032699A1 (fr) * 2005-09-12 2007-03-22 Avdulov, Nikolai Andreevich Isomeres optiques (+) et (-) de trans-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pirido[4,3-b]indole
EP1937263A2 (de) * 2005-10-04 2008-07-02 Medivation, Inc. Hydrierte pyrido-indol-verbindungen zur behandlung von morbus huntington
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2317989C1 (ru) 2006-08-24 2008-02-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EP2066322A2 (de) * 2006-09-20 2009-06-10 Medivation Neurology, Inc. Hydrierte pyrido-[4,3-b]-indole wie z. b. dimebon zur behandlung kognitiver dysfunktionen bei hunden
CA2664099A1 (en) * 2006-09-20 2008-03-27 Medivation Neurology, Inc. Methods and compositions for treating amyotrophic lateral sclerosis (als)
KR20090087009A (ko) * 2006-10-27 2009-08-14 메디베이션 뉴롤로지 인코퍼레이티드 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
RU2329044C1 (ru) * 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2334514C1 (ru) * 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2340342C2 (ru) * 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2008112238A1 (en) * 2007-03-12 2008-09-18 Grey Fox Llc 2, 8-dimethyl-5- [2- (6-methylpyridin-3-yl) -ethyl] -2,3,4, 5-tetrahydro- ih- pyrido [4, 3 -b] indole dihydrochloride (dimebon) for the treatment of chronic pain
CA2683453C (en) * 2007-04-05 2013-06-11 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof
RU2327480C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
RU2338533C1 (ru) * 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2009038764A1 (en) * 2007-09-20 2009-03-26 D2E, Llc Fluoro-containing derivatives of hydrogented pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
TWI447117B (zh) * 2007-10-25 2014-08-01 Medivation Technologies Inc 新穎四環化合物
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
WO2009082268A2 (ru) * 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102083830B (zh) 2008-03-24 2014-11-12 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
JP5586577B2 (ja) * 2008-03-24 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
WO2009125646A1 (ja) * 2008-04-09 2009-10-15 財団法人東京都医学研究機構 Ｔｄｐ－４３蓄積細胞モデル
RU2374245C1 (ru) * 2008-08-22 2009-11-27 Андрей Александрович Иващенко Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
EP2340254B8 (de) * 2008-09-15 2014-05-21 Biovista, Inc. Zusammensetzungen und verfahren zur behandlung von epilepsie
UY32147A (es) 2008-09-29 2010-04-30 Abbott Lab Derivados de indol y de indolina y métodos para usarlos
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
JP5588991B2 (ja) 2008-10-31 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 剛性の部分を有するピリド［４，３−ｂ］インドール
JP5551708B2 (ja) * 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド アゼピノ［４，５−ｂ］インドール化合物およびその使用方法
US20100137215A1 (en) * 2008-11-25 2010-06-03 Concert Pharmaceuticals Inc. Novel tetrahydro-1h-pyrido[4,3-b]indoles
AU2010203356B2 (en) * 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8063032B2 (en) 2009-02-11 2011-11-22 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
EP2236159A3 (de) 2009-03-31 2011-12-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dimebolin enthaltende Zusammensetzungen mit modifizierter Freisetzung
EP2236160A3 (de) 2009-03-31 2011-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Dimebolin enthaltende Zusammensetzungen mit modifizierter Freisetzung
TR200903014A1 (tr) 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
AU2010282990B2 (en) 2009-04-29 2015-11-05 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
BRPI1006602A2 (pt) 2009-04-29 2019-01-15 Medivation Technologies Inc composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
JP5779183B2 (ja) 2009-09-23 2015-09-16 メディベイション テクノロジーズ， インコーポレイテッド ピリド［４，３−ｂ］インドールおよび使用方法
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
WO2011038164A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
WO2011039675A2 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
WO2011039686A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
WO2011039670A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)
RU2428185C1 (ru) * 2009-12-29 2011-09-10 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ НА ОСНОВЕ ГИДРИРОВАННОГО ПИРИДО(4,3-b)ИНДОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕЕ ОСНОВЕ
TR201001117A1 (tr) 2010-02-15 2011-09-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Dimebolin ve memantin kombinasyonları
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
DK2590647T3 (en) 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds
WO2012016707A2 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form for the modified release of dimebolin
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
AU2012254158B2 (en) 2011-02-18 2016-02-04 Medivation Technologies, Inc. Compounds and methods of treating diabetes
DE102012003065A1 (de) * 2012-02-13 2013-08-14 Friedrich-Schiller-Universität Jena Neue bivalente Gammacarbolinderivate sowie deren Herstellung und Verwendung als Antidementiva
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
EP2887805A4 (de) * 2012-08-22 2016-08-17 Medivation Technologies Inc Verbindungen und verfahren zur behandlung von bluthochdruck
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2014207241A1 (en) * 2013-06-28 2014-12-31 Alzprotect NEW Na-SUBSTITUTED CARBOLINE COMPOUNDS USABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP2918792A1 (de) * 2014-03-13 2015-09-16 Siemens Aktiengesellschaft Dampfkraftanlage mit Spindelleckdampfleitung
CN109535157B (zh) * 2018-12-03 2021-10-15 江苏科技大学 一种半蜡梅碱类似物、其合成方法及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
CH508645A (de) 1967-12-08 1971-06-15 Sumitomo Chemical Co Verfahren zur Herstellung von neuen 5-substituierten y-Carbolinderivaten
US3743740A (en) 1968-10-31 1973-07-03 I Zhukova 3,6-dimethyl - 1,2,3,4,4a,9a - hexahydro-ypsilon-carboline dihydrochloride for treating mental diseases
GB1276113A (en) 1969-10-17 1972-06-01 Nii Farmakologii I Khim 3,6-DIMETHYL 1,2,3,4a,9a-HEXAHYDRO-gamma-CARBOLINE DIHYDROCHLORIDE
DE1952800C3 (de) 1969-10-20 1974-04-18 Nautschno-Issledowatelskij Institut Farmakologii I Chimioterapii, Moskau 3,6-Dimethyl-l,2,3,4,4a,9a-hexahydro-gamma-carbolin-dihydrochlorid
US3718657A (en) * 1970-12-03 1973-02-27 Abbott Lab Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines
AR205452A1 (es) * 1973-12-06 1976-05-07 Endo Lab Metodo para preparar nuevos trans-2, 3, 4, 4a, 5, 9b-hexahidro-5-fenil-1h-pirido(4,3-b) indoles
US4174453A (en) * 1973-12-06 1979-11-13 Endo Laboratories, Inc. Trans-hexahydro-pyrido-indoles
SE7414572L (de) * 1973-12-06 1975-06-09 Endo Lab
SE441448B (sv) * 1977-05-23 1985-10-07 Pfizer Sett att framstella hexahydro-gamma-karbolinforeningar
US4636563A (en) * 1985-09-16 1987-01-13 American Home Products Corporation Antipsychotic γ-carbolines
GB8600783D0 (en) 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US4985256A (en) 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US6017957A (en) 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
EP0424179A3 (en) 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5319096A (en) * 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
DE4212529A1 (de) 1992-04-10 1993-10-14 Schering Ag Verwendung von µ-Carbolinen als nicht-kompetitive Glutamat-Antagonisten
US5248690A (en) 1992-07-07 1993-09-28 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US6362160B1 (en) 1993-06-30 2002-03-26 The Johns Hopkins University School Of Medicine Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
RU2140417C1 (ru) 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US6379882B1 (en) 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
CA2394431C (en) 1999-12-16 2015-06-30 Jane Relton Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Also Published As

Publication number Publication date
HK1016893A1 (en) 1999-11-12
US20050096342A1 (en) 2005-05-05
US6187785B1 (en) 2001-02-13
US7071206B2 (en) 2006-07-04
ATE229806T1 (de) 2003-01-15
DE69625518D1 (de) 2003-01-30
CA2269698A1 (en) 1997-05-01
US20060140866A1 (en) 2006-06-29
ES2188793T3 (es) 2003-07-01
CA2269698C (en) 2007-09-18
EP0876818B1 (de) 2002-12-18
US20040044022A1 (en) 2004-03-04
AU7347496A (en) 1997-05-15
WO1997015225A1 (fr) 1997-05-01
EP0876818A2 (de) 1998-11-11
RU2106864C1 (ru) 1998-03-20
DE69625518T2 (de) 2003-09-04
EP0876818A4 (de) 1999-01-07
US20010020028A1 (en) 2001-09-06
US20020115682A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
DK0876818T3 (da) Middel til behnadling af nerodegenerative lidelser
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
PT842934E (pt) Agonistas de 5-ht1f
PT1224205E (pt) Derivados 5-beta-sapogenina e pseudo-sapogenina e sua utilizacao no tratamento de demencia
ES2123521T3 (es) Derivados de indol.
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DK0633879T3 (da) Enantiomert 1-phenyl-2(2-pyridinyl) ethylamin til behandling af neurodegenerative sygdomme
BR0012921A (pt) Compostos calcilìticos
FI905957A0 (fi) Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet.
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
NO20011892D0 (no) 3-tetrahydropyridin-4-yl-indoler for behandling av psykotiske forstyrrelser
TWI245756B (en) Improved process for the preparation of 1,3-substituted indenes
MX10256A (es) Procedimiento para preparar nuevas 3-fenil-7h-tiazolo(3, 2-b) (1, 2, 4) triazin-7-onas.
RU97115054A (ru) Средство для лечения онкологических больных
BR9909878A (pt) 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central
ATE321044T1 (de) C-6 ringsubstituierte pyrido(1,2- a)benzimidazolderivate zur behandlung von störungen des zentralen nervensystems
ITPD960038V0 (it) Associazione di porfirina cationica e sorgente luminosa coerente o noncoerente per il trattamento di infezioni microbiche dell'endodonto e del periimpianto
NO20053612D0 (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet
DK0833638T3 (da) Anvendelse af imidazo[1,5-a]quinoloner som neuroprotektive midler